Research

Scientists establish the safe dose of statins to use in combination with an antibiotic in the treatment of advanced cirrhosis

A study coordinated by researchers of the Clínic-IDIBAPS and published in The Lancet Gastroenterology & Hepatology establishes the safe dose of simvastatin to be used together with rifaximin, an antibiotic that modulates the intestinal microbiome, in patients with advanced cirrhosis. This article is the result of three years of work of the Liverhope Consortium, a project that is part of the Horizon 2020 European research and innovation framework program and has a budget of 6 million euros.